Skip to content

Artificial Intelligence-based Stereotactic Radiation Therapy for Persistent Atrial Fibrillation

Artificial Intelligence-based Stereotactic Radiation Therapy for Persistent Atrial Fibrillation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036811
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Experimental Group:Stereotactic radiation therapy
Control:Radiofrequency ablation

Sponsors

Huashan Hospital affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. having a history of atrial fibrillation or having atrial fibrillation attack during hospitalization and definite diagnosis of atrial fibrillation by ECG / Holter. The diagnostic criteria of atrial fibrillation were: P wave disappeared on ECG or Holter, and F wave with irregular amplitude, shape and spacing was replaced by irregular ventricular wave; 2. aged >18 years old; 3. sinus rhythm could not be maintained by drugs; 4. persistent atrial fibrillation was diagnosed more than 1 year, or persistent atrial fibrillation combined with significant left atrial enlargement (length diameter >=50 mm); 5. patients with persistent atrial fibrillation who failed to receive radiofrequency ablation and refused to accept radiofrequency ablation treatment.

Exclusion criteria

Exclusion criteria: 1. atrial fibrillation caused by valvular disease; 2. with mediastinal and pulmonary lesions; 3. congenital and rheumatic heart disease; 4. history of myocardial infarction; 5. pulmonary vein structure was affected by other diseases except atrial fibrillation; 6. CTA could not be performed due to contrast medium allergy or other reasons; 7. patients with uncontrollable hyperthyroidism, obvious abnormal liver and kidney function, tumor diseases, etc.

Design outcomes

Primary

MeasureTime frame
adverse event;AF BURDEN;

Secondary

MeasureTime frame
quality of life(QoL)SF -12;

Countries

China

Contacts

Public ContactXinping Luo

Huashan Hospital affiliated to Fudan University

luoxp2007@aliyun.com+86 1301783093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026